Delisting risk
XORTX Therapeutics (XRTX)
Develops oral oxypurinol therapies for gout and kidney disease.
$2.42
At close+0.26 (+12.04%)
In millions of USD, except per-share figures
| In millions | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cost of revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | |
| Research & development | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 2 | |
| Selling & marketing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| General & administrative | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 2 |
| Other expenses | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating income | −1 | −1 | −1 | −1 | −1 | −1 | −1 | −1 | −1 | −1 | −1 | −2 |
| 0 | 4 | −2 | 2 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Interest income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other non-operating income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income before tax | −1 | 3 | −3 | 0 | −1 | 0 | −1 | −1 | −1 | −1 | −1 | −2 |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | −2 | 3 | −3 | 0 | −1 | 0 | −1 | −1 | −1 | −1 | −1 | −2 |
| Other adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | −1 | 3 | −3 | 0 | −1 | 0 | −1 | −1 | −1 | −1 | −1 | −2 |
| EPS, basic | −$16.75 | $6.94 | −$1.24 | $0.06 | −$0.20 | $0.19 | −$0.93 | −$0.95 | −$0.65 | −$0.46 | −$0.58 | −$1.05 |
| EPS, diluted | −$16.75 | $6.94 | −$1.24 | $0.06 | −$0.20 | $0.19 | −$0.93 | −$0.95 | −$0.65 | −$0.46 | −$0.58 | −$1.05 |
| Weighted average shares, basic | 0 | 0 | 2 | 3 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 2 |
| Weighted average shares, diluted | 0 | 0 | 2 | 3 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 2 |
| EBITDA | −1 | −1 | −1 | −1 | −1 | −1 | −1 | −1 | −1 | −1 | −1 | −2 |
| Depreciation & amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBIT | −1 | −1 | −1 | −1 | −1 | −1 | −1 | −1 | −1 | −1 | −1 | −2 |